| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92884d107866ba04b6f1aa4a67eed3ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36189 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36189 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-05 |
| filingDate |
2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34f96b89e95fbe40d941b557987bb963
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c93203d7574c883c5a8caf2341931a0a |
| publicationDate |
2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019321641-A1 |
| titleOfInvention |
Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods |
| abstract |
Systems and methods for treating a patient having a blood glucose abnormality, such as type 2 diabetes (T2D), using an electrical signal are disclosed. A representative method for treating a patient includes, based at least in part on a patient indication of a blood glucose abnormality, positioning at least one implantable signal delivery device proximate to a target location at the patient's spinal cord within a vertebral range of from about C8 to about T12. The method further includes directing an electrical signal to the target location via the implantable signal delivery device, wherein the electrical signal has a frequency in a frequency range of from 1.2 kHz to 100 kHz. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11318310-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298539-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786731-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759638-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11534611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11596798-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11229792-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11590352-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11229793-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11247057-B1 |
| priorityDate |
2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |